We have profiled promoter DNA methylation alterations in 272 glioblastoma tumors in the
context of The Cancer Genome Atlas (TCGA). We found that a distinct subset of samples …

Extensive genomic and gene expression studies have been performed in gliomas, but the
epigenetic alterations that characterize different subtypes of gliomas remain largely …

Glioma diagnosis is based on histomorphology and grading; however, such classification
does not have predictive clinical outcome after glioblastomas have developed. To date, no …

Both genome-wide genetic and epigenetic alterations are fundamentally important for the
development of cancers, but the interdependence of these aberrations is poorly understood …

Glioblastoma (GBM) is the most common and malignant type of primary brain tumor in adults
and prognosis of most GBM patients is poor. However, a small percentage of patients show …

Gliomas are a heterogeneous group of brain tumors with distinct biological and clinical
properties. Despite advances in surgical techniques and clinical regimens, treatment of high …

Monoallelic point mutations of the NADP+-dependent isocitrate dehydrogenases IDH1 and
IDH2 occur frequently in gliomas, acute myeloid leukemias, and chondromas, and display …

Although the CpG island methylator phenotype (CIMP) was first identified and has been
most extensively studied in colorectal cancer, the term “CIMP” has been repeatedly used …

Aims Mutations of isocitrate dehydrogenase (IDH) 1/2 affect almost all astrocytomas of WHO
grade II and III. A subset of IDH‐mutant astrocytic tumours progresses to IDH‐mutant …

The outcome of patients with anaplastic gliomas varies considerably. Whether a molecular
classification of anaplastic gliomas based on large-scale genomic or epigenomic analyses …